Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOGAST
2020-000297-17Phase 2Active
- Sponsor
- Hospices Civils de Lyon
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab and ipatasertib in gastric adenocarcinoma, sponsored by Hospices Civils de Lyon. Primary endpoint: Objective response rate. Started Jun 2020; status: active.
02
Drugs
atezolizumabbevacizumabipatasertib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2020-000297-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000297-17.